Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine
ADP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine 5'-phosphate
ATP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine
ADP + 3'-ethynylcytidine 5'-monophosphate
-
-
-
?
ATP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine
ADP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine 5'-phosphate
ATP + 2-thiocytidine
ADP + 2-thiocytidine 5'-monophosphate
ATP + 3'-C-ethynylcytidine
ADP + 3'-C-ethynylcytidine 5'-phosphate
ATP + 3'-C-ethynylcytidine 5'-diphosphate
ADP + 3'-C-ethynylcytidine 5'-triphosphate
ATP + 3'-C-ethynylcytidine 5'-phosphate
ADP + 3'-C-ethynylcytidine 5'-diphosphate
ATP + 3'-C-ethynyluridine
ADP + 3'-C-ethynyluridine 5'-phosphate
ATP + 3'-C-ethynyluridine 5'-diphosphate
ADP + 3'-C-ethynyluridine 5'-triphosphate
ATP + 3'-C-ethynyluridine 5'-phosphate
ADP + 3'-C-ethynyluridine 5'-diphosphate
ATP + 3'-deoxy-3'-ethynylcytidine
ADP + 3'-deoxy-3'-ethynylcytidine 5'-monophosphate
-
recombinant uridine kinase, 20% of activity with uridine
-
?
ATP + 3'-deoxy-3'-ethynyluridine
ADP + 3'-deoxy-3'-ethynyluridine 5'-monophosphate
-
recombinant uridine kinase, 20% of activity with uridine
-
?
ATP + 3'-ethynylcytidine
ADP + 3'-ethynylcytidine 5'-monophosphate
i.e. 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine
-
-
?
ATP + 3'-ethynylcytidine 5'-diphosphate
ADP + 3'-ethynylcytidine 5'-triphosphate
-
-
-
?
ATP + 3'-ethynylcytidine 5'-monophosphate
ADP + 3'-ethynylcytidine 5'-diphosphate
-
-
-
?
ATP + 3'-ethynyluridine
ADP + 3'-ethynyluridine 5'-monophosphate
i.e. 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine
-
-
?
ATP + 3'-ethynyluridine 5'-diphosphate
ADP + 3'-ethynyluridine 5'-triphosphate
-
-
-
?
ATP + 3'-ethynyluridine 5'-monophosphate
ADP + 3'-ethynyluridine 5'-diphosphate
-
-
-
?
ATP + 3,4,5,6-tetrahydrouridine
ADP + 3,4,5,6-tetrahydrouridine 5'-monophosphate
ATP + 3-deazauridine
ADP + 3-deazauridine 5'-monophosphate
recombinant uridine kinase 2, 49% of activity with uridine
-
?
ATP + 3-deazauridine
ADP + ?
-
-
-
?
ATP + 3-methyluridine
ADP + 3-methyluridine 5'-monophosphate
recombinant uridine kinase 2, 18% of activity with uridine
-
?
ATP + 4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2(1H)-one
ADP + [(3S,4S,5R)-3-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-fluoro-4,5-dihydroxycyclopent-1-en-1-yl]methyl phosphate
-
-
-
ir
ATP + 4-thiouridine
ADP + 4-thiouridine 5'-monophosphate
ATP + 5-azacytidine
ADP + 5-azacytidine 5'-monophosphate
-
-
-
?
ATP + 5-azacytidine
ADP + ?
-
-
-
?
ATP + 5-bromouridine
ADP + 5-bromouridine 5'-monophosphate
ATP + 5-fluorocytidine
ADP + 5-fluorocytidine 5'-monophosphate
ATP + 5-fluorocytidine
ADP + ?
-
-
-
?
ATP + 5-fluorouridine
ADP + 5-fluoro-UMP
-
-
-
?
ATP + 5-fluorouridine
ADP + 5-fluorouridine 5'-monophosphate
ATP + 5-fluorouridine
ADP + ?
-
-
-
?
ATP + 5-hydroxyuridine
ADP + 5-hydroxyuridine 5'-monophosphate
ATP + 5-methoxyuridine
ADP + 5-methoxyuridine 5'-monophosphate
ATP + 5-methylcytidine
ADP + 5-methylcytidine 5'-monophosphate
ATP + 6-azacytidine
ADP + 6-azacytidine 5'-monophosphate
recombinant uridine kinase 2, 75% of activity with uridine
-
?
ATP + 6-azauridine
ADP + 6-azauridine 5'-monophosphate
recombinant uridine kinase 1, 38% of activity with uridine, recombinant uridine kinase 2, 148% of activity with uridine
-
?
ATP + 6-azauridine
ADP + ?
-
-
-
?
ATP + cyclopentenyl cytosine
ADP + ?
-
-
-
?
ATP + cyclopentenyl uracil
ADP + ?
-
-
-
?
ATP + cyclopentenyl-cytosine
ADP + cyclopentenylcytosine 5'-monophosphate
-
-
-
?
ATP + cyclopentenylcytosine
ADP + cyclopentenylcytosine 5'-monophosphate
-
recombinant uridine kinase, 12% of activity with uridine
-
?
ATP + fluorocyclopentenylcytosine
?
an orally available cytidine analogue, RX-3117
-
-
?
ATP + N4-acetylcytidine
ADP + N4-acetylcytidine 5'-monophosphate
ATP + N4-aminocytidine
ADP + N4-aminocytidine 5'-monophosphate
recombinant uridine kinase 1, 20% of activity with uridine
-
?
ATP + N4-anisoylcytidine
ADP + N4-anisoylcytidine 5'-monophosphate
ATP + N4-benzoylcytidine
ADP + N4-benzoylcytidine 5'-monophosphate
ATP + ribavirin
ADP + ribavirin monophosphate
-
13% of substrate phosphorylated, within 2 h incubation
-
-
?
cytidine + ATP
CMP + ADP
-
-
-
?
dATP + cytidine
dADP + CMP
-
recombinant uridine kinase
-
?
dATP + uridine
dADP + UMP
-
recombinant uridine kinase
-
?
dCTP + cytidine
dCDP + CMP
-
recombinant uridine kinase
-
?
dUTP + cytidine
dUDP + CMP
-
recombinant uridine kinase
-
?
dUTP + uridine
dUDP + UMP
-
recombinant uridine kinase
-
?
GTP + uridine
UMP + GDP
-
-
?
uridine + ATP
UMP + ADP
-
-
-
?
additional information
?
-
ATP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine
ADP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine 5'-phosphate
-
-
-
-
?
ATP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine
ADP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine 5'-phosphate
-
UCK2 enzyme activity required to produce the antitumoral active metabolite
-
-
?
ATP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine
ADP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine 5'-phosphate
-
-
-
-
?
ATP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine
ADP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine 5'-phosphate
-
UCK2 enzyme activity required to produce the antitumoral active metabolite
-
-
?
ATP + 2-thiocytidine
ADP + 2-thiocytidine 5'-monophosphate
recombinant uridine kinase 2, 86% of activity with uridine
-
?
ATP + 2-thiocytidine
ADP + 2-thiocytidine 5'-monophosphate
recombinant uridine kinase 1, 20% of activity with uridine
-
?
ATP + 3'-C-ethynylcytidine
ADP + 3'-C-ethynylcytidine 5'-phosphate
i.e. 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine
-
-
ir
ATP + 3'-C-ethynylcytidine
ADP + 3'-C-ethynylcytidine 5'-phosphate
-
i.e. 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine
-
-
ir
ATP + 3'-C-ethynylcytidine 5'-diphosphate
ADP + 3'-C-ethynylcytidine 5'-triphosphate
-
-
-
?
ATP + 3'-C-ethynylcytidine 5'-diphosphate
ADP + 3'-C-ethynylcytidine 5'-triphosphate
-
-
-
-
?
ATP + 3'-C-ethynylcytidine 5'-phosphate
ADP + 3'-C-ethynylcytidine 5'-diphosphate
-
-
-
?
ATP + 3'-C-ethynylcytidine 5'-phosphate
ADP + 3'-C-ethynylcytidine 5'-diphosphate
-
-
-
-
?
ATP + 3'-C-ethynyluridine
ADP + 3'-C-ethynyluridine 5'-phosphate
i.e. 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine
-
-
?
ATP + 3'-C-ethynyluridine
ADP + 3'-C-ethynyluridine 5'-phosphate
-
i.e. 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine
-
-
?
ATP + 3'-C-ethynyluridine 5'-diphosphate
ADP + 3'-C-ethynyluridine 5'-triphosphate
-
-
-
?
ATP + 3'-C-ethynyluridine 5'-diphosphate
ADP + 3'-C-ethynyluridine 5'-triphosphate
-
-
-
-
?
ATP + 3'-C-ethynyluridine 5'-phosphate
ADP + 3'-C-ethynyluridine 5'-diphosphate
-
-
-
?
ATP + 3'-C-ethynyluridine 5'-phosphate
ADP + 3'-C-ethynyluridine 5'-diphosphate
-
-
-
-
?
ATP + 3,4,5,6-tetrahydrouridine
ADP + 3,4,5,6-tetrahydrouridine 5'-monophosphate
recombinant uridine kinase 1, 13% of activity with uridine
-
?
ATP + 3,4,5,6-tetrahydrouridine
ADP + 3,4,5,6-tetrahydrouridine 5'-monophosphate
recombinant uridine kinase 2, 81% of activity with uridine
-
?
ATP + 4-thiouridine
ADP + 4-thiouridine 5'-monophosphate
recombinant uridine kinase 1, 122% of activity with uridine
-
?
ATP + 4-thiouridine
ADP + 4-thiouridine 5'-monophosphate
recombinant uridine kinase 2, 125% of activity with uridine
-
?
ATP + 5-bromouridine
ADP + 5-bromouridine 5'-monophosphate
recombinant uridine kinase 1, 50% of activity with uridine
-
?
ATP + 5-bromouridine
ADP + 5-bromouridine 5'-monophosphate
recombinant uridine kinase 2,6% of activity with uridine
-
?
ATP + 5-fluorocytidine
ADP + 5-fluorocytidine 5'-monophosphate
recombinant uridine kinase 1, 37% of activity with uridine
-
?
ATP + 5-fluorocytidine
ADP + 5-fluorocytidine 5'-monophosphate
recombinant uridine kinase 2, 184% of activity with uridine
-
?
ATP + 5-fluorouridine
ADP + 5-fluorouridine 5'-monophosphate
-
-
-
?
ATP + 5-fluorouridine
ADP + 5-fluorouridine 5'-monophosphate
-
recombinant uridine kinase
-
?
ATP + 5-fluorouridine
ADP + 5-fluorouridine 5'-monophosphate
recombinant uridine kinase 2, 89% of activity with uridine
-
?
ATP + 5-hydroxyuridine
ADP + 5-hydroxyuridine 5'-monophosphate
recombinant uridine kinase 1, 14% of activity with uridine
-
?
ATP + 5-hydroxyuridine
ADP + 5-hydroxyuridine 5'-monophosphate
recombinant uridine kinase 2, 12% of activity with uridine
-
?
ATP + 5-methoxyuridine
ADP + 5-methoxyuridine 5'-monophosphate
recombinant uridine kinase 1, 122% of activity with uridine
-
?
ATP + 5-methoxyuridine
ADP + 5-methoxyuridine 5'-monophosphate
recombinant uridine kinase 2, 92% of activity with uridine
-
?
ATP + 5-methylcytidine
ADP + 5-methylcytidine 5'-monophosphate
recombinant uridine kinase 1, 9% of activity with uridine
-
?
ATP + 5-methylcytidine
ADP + 5-methylcytidine 5'-monophosphate
recombinant uridine kinase 2, 30% of activity with uridine
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
rate limiting enzyme of the pyrimidine-nucleotide salvage pathway
-
-
?
ATP + cytidine
ADP + CMP
rate limiting enzyme of the pyrimidine-nucleotide salvage pathway
-
-
?
ATP + cytidine
ADP + CMP
rate limiting enzyme of the pyrimidine-nucleotide salvage pathway, essential for cell proliferation, UCK 2 involved in tumor formation
-
-
?
ATP + cytidine
ADP + CMP
-
89% of substrate phosphorylated, within 2 h incubation
-
-
?
ATP + cytidine
ADP + CMP
the enzyme is responsible for the phosphorylation of uridine and cytidine to their corresponding monophosphate in a salvage pathway of pyrimidine nucleotides biosynthesis
-
-
?
ATP + N4-acetylcytidine
ADP + N4-acetylcytidine 5'-monophosphate
recombinant uridine kinase 1, 142% of activity with uridine
-
?
ATP + N4-acetylcytidine
ADP + N4-acetylcytidine 5'-monophosphate
recombinant uridine kinase 2, 84% of activity with uridine
-
?
ATP + N4-anisoylcytidine
ADP + N4-anisoylcytidine 5'-monophosphate
recombinant uridine kinase 2, 12% of activity with uridine
-
?
ATP + N4-anisoylcytidine
ADP + N4-anisoylcytidine 5'-monophosphate
recombinant uridine kinase 1, 20% of activity with uridine
-
?
ATP + N4-benzoylcytidine
ADP + N4-benzoylcytidine 5'-monophosphate
recombinant uridine kinase 1, 68% of activity with uridine
-
?
ATP + N4-benzoylcytidine
ADP + N4-benzoylcytidine 5'-monophosphate
recombinant uridine kinase 2, 51% of activity with uridine
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
no activity with adenosine, guanosine and deoxyribonucleotides, no activity with CTP and UTP
-
?
ATP + uridine
ADP + UMP
-
rate limiting enzyme of the pyrimidine-nucleotide salvage pathway
-
-
?
ATP + uridine
ADP + UMP
rate limiting enzyme of the pyrimidine-nucleotide salvage pathway
-
-
?
ATP + uridine
ADP + UMP
rate limiting enzyme of the pyrimidine-nucleotide salvage pathway, essential for cell proliferation, UCK 2 involved in tumor formation
-
-
?
ATP + uridine
ADP + UMP
-
56% of substrate phosphorylated, within 2 h incubation
-
-
?
ATP + uridine
ADP + UMP
the enzyme is responsible for the phosphorylation of uridine and cytidine to their corresponding monophosphate in a salvage pathway of pyrimidine nucleotides biosynthesis
-
-
?
additional information
?
-
uridine-cytidine kinase (UCK) catalyzes the phosphorylation of uridine, cytidine, and several pyrimidine ribonucleoside analogues
-
-
-
additional information
?
-
uridine-cytidine kinase (UCK) catalyzes the phosphorylation of uridine, cytidine, and several pyrimidine ribonucleoside analogues
-
-
-
additional information
?
-
-
uridine-cytidine kinase (UCK) catalyzes the phosphorylation of uridine, cytidine, and several pyrimidine ribonucleoside analogues
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine
ADP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine 5'-phosphate
-
UCK2 enzyme activity required to produce the antitumoral active metabolite
-
-
?
ATP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine
ADP + 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine 5'-phosphate
-
UCK2 enzyme activity required to produce the antitumoral active metabolite
-
-
?
ATP + 3'-C-ethynylcytidine
ADP + 3'-C-ethynylcytidine 5'-phosphate
ATP + 3'-C-ethynylcytidine 5'-diphosphate
ADP + 3'-C-ethynylcytidine 5'-triphosphate
ATP + 3'-C-ethynylcytidine 5'-phosphate
ADP + 3'-C-ethynylcytidine 5'-diphosphate
ATP + 3'-C-ethynyluridine
ADP + 3'-C-ethynyluridine 5'-phosphate
ATP + 3'-C-ethynyluridine 5'-diphosphate
ADP + 3'-C-ethynyluridine 5'-triphosphate
ATP + 3'-C-ethynyluridine 5'-phosphate
ADP + 3'-C-ethynyluridine 5'-diphosphate
ATP + 3'-C-ethynylcytidine
ADP + 3'-C-ethynylcytidine 5'-phosphate
i.e. 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine
-
-
ir
ATP + 3'-C-ethynylcytidine
ADP + 3'-C-ethynylcytidine 5'-phosphate
-
i.e. 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine
-
-
ir
ATP + 3'-C-ethynylcytidine 5'-diphosphate
ADP + 3'-C-ethynylcytidine 5'-triphosphate
-
-
-
?
ATP + 3'-C-ethynylcytidine 5'-diphosphate
ADP + 3'-C-ethynylcytidine 5'-triphosphate
-
-
-
-
?
ATP + 3'-C-ethynylcytidine 5'-phosphate
ADP + 3'-C-ethynylcytidine 5'-diphosphate
-
-
-
?
ATP + 3'-C-ethynylcytidine 5'-phosphate
ADP + 3'-C-ethynylcytidine 5'-diphosphate
-
-
-
-
?
ATP + 3'-C-ethynyluridine
ADP + 3'-C-ethynyluridine 5'-phosphate
i.e. 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine
-
-
?
ATP + 3'-C-ethynyluridine
ADP + 3'-C-ethynyluridine 5'-phosphate
-
i.e. 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine
-
-
?
ATP + 3'-C-ethynyluridine 5'-diphosphate
ADP + 3'-C-ethynyluridine 5'-triphosphate
-
-
-
?
ATP + 3'-C-ethynyluridine 5'-diphosphate
ADP + 3'-C-ethynyluridine 5'-triphosphate
-
-
-
-
?
ATP + 3'-C-ethynyluridine 5'-phosphate
ADP + 3'-C-ethynyluridine 5'-diphosphate
-
-
-
?
ATP + 3'-C-ethynyluridine 5'-phosphate
ADP + 3'-C-ethynyluridine 5'-diphosphate
-
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
-
?
ATP + cytidine
ADP + CMP
-
-
-
?
ATP + cytidine
ADP + CMP
-
rate limiting enzyme of the pyrimidine-nucleotide salvage pathway
-
-
?
ATP + cytidine
ADP + CMP
rate limiting enzyme of the pyrimidine-nucleotide salvage pathway
-
-
?
ATP + cytidine
ADP + CMP
rate limiting enzyme of the pyrimidine-nucleotide salvage pathway, essential for cell proliferation, UCK 2 involved in tumor formation
-
-
?
ATP + cytidine
ADP + CMP
the enzyme is responsible for the phosphorylation of uridine and cytidine to their corresponding monophosphate in a salvage pathway of pyrimidine nucleotides biosynthesis
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
-
?
ATP + uridine
ADP + UMP
-
-
-
?
ATP + uridine
ADP + UMP
-
rate limiting enzyme of the pyrimidine-nucleotide salvage pathway
-
-
?
ATP + uridine
ADP + UMP
rate limiting enzyme of the pyrimidine-nucleotide salvage pathway
-
-
?
ATP + uridine
ADP + UMP
rate limiting enzyme of the pyrimidine-nucleotide salvage pathway, essential for cell proliferation, UCK 2 involved in tumor formation
-
-
?
ATP + uridine
ADP + UMP
the enzyme is responsible for the phosphorylation of uridine and cytidine to their corresponding monophosphate in a salvage pathway of pyrimidine nucleotides biosynthesis
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1E)-[[4-(4-tert-butylphenyl)-5-cyano-6-hydroxypyrimidin-2-yl]sulfanyl]-N-(2-methoxyphenyl)ethanimidic acid
-
(1Z)-[([5-[(4-fluorophenyl)methyl]-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl)sulfanyl]-N-(2-methylphenyl)ethanimidic acid
-
1-(p-toluenesulfonyl) cytosine
-
44% inhibition at 0.001 mM
2-[(5-cyano-4-hydroxy-6-phenylpyrimidin-2-yl)sulfanyl]-N-(4-ethylphenyl)acetamide
-
2-[[1-(4-fluorophenyl)-4-oxo-5H-pyrazolo[3,4-d]pyrimidin-6-yl]sulfanyl]-N-[2-(trifluoromethyl)phenyl]acetamide
-
2-[[4-(4-tert-butylphenyl)-5-cyano-6-hydroxypyrimidin-2-yl]sulfanyl]-N-(4-chlorophenyl)acetamide
-
3-(2-[[9-methoxy-2-(4-methylphenyl)-5H-[1]benzopyrano[2,3-d]pyrimidin-4-yl]sulfanyl]acetamido)benzoic acid
-
3-(2-[[9-methyl-2-(4-methylphenyl)-5H-[1]benzopyrano[2,3-d]pyrimidin-4-yl]sulfanyl]acetamido)benzoic acid
-
3-[[2-[[2-(4-fluorophenyl)-5H-chromeno[2,3-d]pyrimidin-4-yl]sulfanyl]acetyl]amino]benzoic acid
-
4-(2-[[9-methyl-2-(4-methylphenyl)-5H-[1]benzopyrano[2,3-d]pyrimidin-4-yl]sulfanyl]acetamido)benzoic acid
-
4-[[2-[[2-(4-methoxyphenyl)-5H-chromeno[2,3-d]pyrimidin-4-yl]sulfanyl]acetyl]amino]benzoic acid
-
bhutkesoside A
isolated from Ligusticopsis wallichiana (Apiaceae). Hydrophobic interactions are predicted for bhutkesoside A with Phe83
bhutkesoside B
isolated from Ligusticopsis wallichiana (Apiaceae). Bhutkesoside B is estimated to inhibit UCK2 protein by binding to the catalytic active site of ATP, thus inhibiting ATP from binding to its active site in the UCK2 protein. Hydrophobic interactions are predicted for bhutkesoside B with Ala30
N-(3,5-dimethylphenyl)-2-[([5-[(4-fluorophenyl)methyl]-7-oxo-2,5,6,7-tetrahydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl)sulfanyl]acetamide
inhibits 3'-ethynylcytidine 5'-triphosphate (5-EU) salvage by about 40% at 0.05 mM
N-(4-bromophenyl)-2-[[1-(4-fluorophenyl)-4-hydroxy-1H-pyrazolo[3,4-d]pyrimidin-6-yl]sulfanyl]acetamide
-
CTP
feedback inhibition
CTP
-
feedback inhibition
UTP
feedback inhibition
UTP
-
feedback inhibition
additional information
establishment and miniaturization of an in vitro assay for UCK2 activity and high-throughput screen against an about 40,000-compound library to generate drug-like leads. Analysis of the structures, activities, and modes of inhibition of the most promising hits, overview. Non-competitive UCK2 inhibitors are identified which are able to suppress nucleoside salvage in cells both in the presence and absence of dihydroorotate dehydrogenase (DHODH) inhibitors. No inhibition by 2-[[9-methyl-2-(4-methylphenyl)-5H-[1]benzopyrano[2,3-d]pyrimidin-4-yl]sulfanyl]-N-phenylacetamide, and (1Z)-N-(4-fluorophenyl)[([5-[(4-fluorophenyl)methyl]-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl)sulfanyl]ethanimidic acid
-
additional information
-
establishment and miniaturization of an in vitro assay for UCK2 activity and high-throughput screen against an about 40,000-compound library to generate drug-like leads. Analysis of the structures, activities, and modes of inhibition of the most promising hits, overview. Non-competitive UCK2 inhibitors are identified which are able to suppress nucleoside salvage in cells both in the presence and absence of dihydroorotate dehydrogenase (DHODH) inhibitors. No inhibition by 2-[[9-methyl-2-(4-methylphenyl)-5H-[1]benzopyrano[2,3-d]pyrimidin-4-yl]sulfanyl]-N-phenylacetamide, and (1Z)-N-(4-fluorophenyl)[([5-[(4-fluorophenyl)methyl]-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl)sulfanyl]ethanimidic acid
-
additional information
discovery of two diacetylene glycosides as human uridine-cytidine kinase 2 inhibitors, in an in silico approach. Molecular ligand-protein docking, using uridine-cytidine kinase 2 structure PDB ID 1UDW. Druggability likeliness property of Bhutkesoside A and Bhutkesoside B as GPCR ligands, ion channel modulators (ICM), kinase inhibitors (KI), nuclear receptor ligands (NRL), protease inhibitors (PI) and enzyme inhibitors (EI) are studied, and results are retrieved as bioactivity scores, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
Preliminary studies of the uridine kinase activity of human colorectal adenocarcinomas.
Adenosarcoma
Uridine kinase activity in human tumors.
Breast Neoplasms
Overexpression of Uridine-Cytidine Kinase 2 Correlates with Breast Cancer Progression and Poor Prognosis.
Carcinoid Tumor
Pulmonary carcinoid tumors: enzymic discriminants, growth rate, and early age of inception.
Carcinoma
Enzyme pathology of human mesotheliomas.
Carcinoma
Increased uridine kinase (ATP: uridine 5'-phosphotransferase; EC 2.7.1.48) activity in human and rat tumors.
Carcinoma
Pulmonary carcinoid tumors: enzymic discriminants, growth rate, and early age of inception.
Carcinoma
Specific activities of uridine phosphorylase and uridine kinase in Ehrlich ascites carcinoma cells and 6-azauracil- and 6-azauridine-treated sublines in successive transplant generations.
Carcinoma
Uridine kinase from Ehrlich ascites carcinoma. Purification and properties of homogeneous enzyme.
Carcinoma
Uridine phosphorylase and uridine kinase activities of the Ehrlich ascites carcinoma.
Carcinoma, Ehrlich Tumor
Homogeneous uridine kinase from Ehrlich ascites tumor: substrate specificity and inhibition by bisubstrate analogs.
Carcinoma, Ehrlich Tumor
Regulation of uridine kinase. Evidence for a regulatory site.
Carcinoma, Ehrlich Tumor
The partial purification and properties of uridine kinase from Ehrlich ascites tumor cells.
Carcinoma, Ehrlich Tumor
Uridine kinase from Ehrlich ascites carcinoma. Purification and properties of homogeneous enzyme.
Carcinoma, Hepatocellular
Expression Levels of the Uridine-Cytidine Kinase Like-1 Protein As a Novel Prognostic Factor for Hepatitis C Virus-Associated Hepatocellular Carcinomas.
Carcinoma, Hepatocellular
Increased uridine kinase (ATP: uridine 5'-phosphotransferase; EC 2.7.1.48) activity in human and rat tumors.
Carcinoma, Hepatocellular
Relationship between uridine kinase activity and rate of incorporation of uridine into acid-soluble pool and into RNA during growth cycle of rat hepatoma cells.
Carcinoma, Hepatocellular
UCK2 upregulation might serve as an indicator of unfavorable prognosis of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Uridine kinase molecular species and uridine uptake in some variants of rat hepatomas.
Carcinoma, Hepatocellular
Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the Stat3 pathway.
Carcinoma, Hepatocellular
Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
Carcinoma, Hepatocellular
[Enzymes of anabolic and catabolic nucleic acid pathways in human hepatomas, in liver of healthy persons, and in liver of patients with cancer of gastrointestinal tract]
Carcinoma, Hepatocellular
[Isolation and properties or uridine kinase from Zajdela hepatoma cells]
Carcinoma, Squamous Cell
Pulmonary carcinoid tumors: enzymic discriminants, growth rate, and early age of inception.
Cryptorchidism
Cellular distribution, developmental changes and effects of cryptorchidism on uridine kinase in the rat testis.
Encephalomyelitis, Western Equine
Uridine kinase level in cells infected with western equine encephalomyelitis, vesicular stomatitis, pseudorabies and polyoma viruses.
Fibrosarcoma
Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells.
Hepatitis C
Expression Levels of the Uridine-Cytidine Kinase Like-1 Protein As a Novel Prognostic Factor for Hepatitis C Virus-Associated Hepatocellular Carcinomas.
Hyperthyroidism
Effects of thyroid hormone on UTP content and uridine kinase activity of rat heart and skeletal muscle.
Hyperthyroidism
Thyroxine effect upon activity of uridine kinase in developing rat cerebellum.
Hypothyroidism
Effect of hypothyroidism on aspartate transcarbamylase, uridine kinase, and DNA biosynthesis during cerebellar development in the rat.
Infections
Changes in the activities of nucleoside triphosphatases and nucleoside kinases in Vero cells infected with Simian virus 40.
Infections
EFFECTS OF AGE OF CULTURE AND VACCINIA INFECTION ON URIDINE KINASE ACTIVITY OF L-CELLS.
Infections
Increase of uridine kinase activity in Escherichia coli B following T2-phage infection or chloramphenicol treatment.
Infections
Overexpression of Escherichia coli udk mimics the absence of T7 Gp2 function and thereby abrogates successful infection by T7 phage.
Leukemia
Biological effects of 5-azacytidine in eukaryotes.
Leukemia
Deubiquitinase USP28 inhibits ubiquitin ligase KLHL2-mediated uridine-cytidine kinase 1 degradation and confers sensitivity to 5'-azacytidine-resistant human leukemia cells.
Leukemia
Properties of uridine-cytidine kinase derived from L1210 leukemia cells.
Leukemia
Uridine kinase activities in normal and neoplastic lymphoid cells.
Leukemia
[Activities of enzymes converting 5-fluorouracil to 5-fluorouridine-5' monophosphate and 5-fluorodeoxyuridine-5' monophosphate in subcultured cell lines and solid tumor tissues]
Leukemia, Lymphocytic, Chronic, B-Cell
Uridine kinase activities in normal and neoplastic lymphoid cells.
Leukemia, Lymphoid
Uridine kinase activities in normal and neoplastic lymphoid cells.
Liver Neoplasms, Experimental
Early temporal changes in the uridine kinase isozyme profile of the Novikoff hepatoma in response to 5-azacytidine treatment.
Liver Neoplasms, Experimental
Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma.
Lung Neoplasms
Uridine kinase, adenylate kinase, and guanase in human lung tumors.
Lung Neoplasms
Uridine-cytidine kinase 2 (UCK2): A potential diagnostic and prognostic biomarker for lung cancer.
Lymphoma
Some properties of uridine-cytidine kinase from a human malignant lymphoma.
Lymphoma, Non-Hodgkin
Uridine kinase activities in normal and neoplastic lymphoid cells.
Mastocytoma
Uridine kinase activities in normal and neoplastic lymphoid cells.
Melanoma
METTL3-induced UCK2 m6A hypermethylation promotes melanoma cancer cell metastasis via the WNT/?-catenin pathway.
Mesothelioma
Enzyme pathology of human mesotheliomas.
Neoplasm Metastasis
METTL3-induced UCK2 m6A hypermethylation promotes melanoma cancer cell metastasis via the WNT/?-catenin pathway.
Neoplasm Metastasis
Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the Stat3 pathway.
Neoplasms
A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma.
Neoplasms
Activities of various enzymes of pyrimidine nucleotide and DNA syntheses in normal and neoplastic human tissues.
Neoplasms
Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines.
Neoplasms
Coprecipitation of active uridine kinase and phosphomonoesterase from rat kidney by Zn2+-ions. III. Enzymes relevant to cancer chemotherapy.
Neoplasms
Crude Extracts, Flavokawain B and Alpinetin Compounds from the Rhizome of Alpinia mutica Induce Cell Death via UCK2 Enzyme Inhibition and in Turn Reduce 18S rRNA Biosynthesis in HT-29 Cells.
Neoplasms
Cyclopentenyl uracil: an effective inhibitor of uridine salvage in vivo.
Neoplasms
Determination of uridine kinase activity in some human tumours and in leucaemic cells using 4,5-C-14--azauridine as substrate.
Neoplasms
Determination of uridine kinase activity in some human tumours and normal tissues, using 4,5-14-C-6-azauridine as substrate.
Neoplasms
Downregulation of uridine-cytidine kinase like-1 decreases proliferation and enhances tumor susceptibility to lysis by apoptotic agents and natural killer cells.
Neoplasms
Enzyme pathology and the histologic categorization of human lung tumors: the continuum of quantitative biochemical indices of neoplasticity.
Neoplasms
Enzyme-Driven Chemo-and Radiation-Therapy with 12 Pyrimidine Nucleoside Analogs Not Yet in the Clinic.
Neoplasms
Enzymes relevant to cancer chemotherapy II. Heterogeneity of rat kidney uridine kinase following chromatography on Sepharose 6B coupled to N4-(5-amino-Pentyl)-cytidine.
Neoplasms
Homogeneous uridine kinase from Ehrlich ascites tumor: substrate specificity and inhibition by bisubstrate analogs.
Neoplasms
In Silico Discovery of Potential Uridine-Cytidine Kinase 2 Inhibitors from the Rhizome of Alpinia mutica.
Neoplasms
Increased uridine kinase (ATP: uridine 5'-phosphotransferase; EC 2.7.1.48) activity in human and rat tumors.
Neoplasms
Inhibition of Newcastle disease virus replication by 6-azauridine. I. Inefficacy of purified uridine kinase, effect of adenosine-5'-triphosphate.
Neoplasms
Involvement of the uridine cytidine kinase 2 enzyme in cancer cell death: A molecular crosstalk between the enzyme and cellular apoptosis induction.
Neoplasms
Preliminary studies of the uridine kinase activity of human colorectal adenocarcinomas.
Neoplasms
Regulation of enzymic activity by metabolites. I. Uridine-cytidine kinase of Novikoff ascites rat tumor.
Neoplasms
Regulation of uridine kinase. Evidence for a regulatory site.
Neoplasms
Role of the uridine/cytidine kinase 2 mutation in cellular sensitiveness toward 3'-ethynylcytidine treatment of human cancer cells.
Neoplasms
Role of uridine phosphorylase in the anabolism of 5-fluorouracil.
Neoplasms
RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment.
Neoplasms
Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2.
Neoplasms
Synthesis and biologic study of IV-14, a new ribonucleoside radiotracer for tumor visualization.
Neoplasms
The partial purification and properties of uridine kinase from Ehrlich ascites tumor cells.
Neoplasms
UCK2 upregulation might serve as an indicator of unfavorable prognosis of hepatocellular carcinoma.
Neoplasms
Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma.
Neoplasms
Uridine kinase activities in normal and neoplastic lymphoid cells.
Neoplasms
Uridine kinase activity in human tumors.
Neoplasms
Uridine kinase from Ehrlich ascites carcinoma. Purification and properties of homogeneous enzyme.
Neoplasms
Uridine kinase, adenylate kinase, and guanase in human lung tumors.
Neoplasms
Uridine-cytidine kinase 2 (UCK2): A potential diagnostic and prognostic biomarker for lung cancer.
Neoplasms
Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the Stat3 pathway.
Neoplasms
Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
Neoplasms
Uridine-cytidine kinase from a murine neoplasm.
Neoplasms
Uridine-cytidine kinase from Novikoff ascites rat tumor and Bacillus stearothermophilus.
Neoplasms
Uridine-cytidine kinase. Purification from a murine neoplasm and characterization of the enzyme.
Neoplasms
[Activities of enzymes converting 5-fluorouracil to 5-fluorouridine-5' monophosphate and 5-fluorodeoxyuridine-5' monophosphate in subcultured cell lines and solid tumor tissues]
Neoplasms
[Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]
Neuroblastoma
Adverse effects of hyperbaric oxygen on [3H]uridine incorporation and uridine kinase activity in B104 rat neuroblastoma cells.
Neuroblastoma
Purification, activity, and expression levels of two uridine-cytidine kinase isoforms in neuroblastoma cell lines.
Newcastle Disease
Inhibition of Newcastle disease virus replication by 6-azauridine. I. Inefficacy of purified uridine kinase, effect of adenosine-5'-triphosphate.
Pancreatic Neoplasms
Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer.
Pseudorabies
Uridine kinase level in cells infected with western equine encephalomyelitis, vesicular stomatitis, pseudorabies and polyoma viruses.
Sarcoma
Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma.
Sarcoma
[Uridine-cytidine kinase isoenzymes of rat sarcoma M-1]
Sarcoma, Avian
Induction of deoxycytidylate deaminase and uridine kinase and activation of cellular DNA synthesis in the course of transformation of chicken embryo cells infected by Rous sarcoma virus in vitro.
Sarcoma, Yoshida
Intracellular distribution of various enzymes concerned with DNA synthesis from normal and regenerating rat liver, and Yoshida sarcoma.
Starvation
Appropriate leucine supplementation promotes glucose metabolism and enhances energy homeostasis in juvenile crucian carp (Carassius auratus gibelio var. CAS III).
Starvation
Uridine kinase activities in developing, adult and neoplastic rat tissues.
Stroke
Nifedipine and nimodipine competitively inhibit uridine kinase and orotidine-phosphate decarboxylase: theoretical relevance to poor outcome in stroke.
Urinary Bladder Neoplasms
Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer.
Vaccinia
EFFECTS OF AGE OF CULTURE AND VACCINIA INFECTION ON URIDINE KINASE ACTIVITY OF L-CELLS.
Vesicular Stomatitis
Uridine kinase level in cells infected with western equine encephalomyelitis, vesicular stomatitis, pseudorabies and polyoma viruses.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
drug target
1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine (ECyd) is a potent inhibitor of RNA polymerase I and shows anticancer activity to various human solid tumors. ECyd is phosphorylated to 3'-ethynylcytidine 5'-monophosphate by uridine/cytidine kinase 2 (UCK2) and subsequently further to diphosphate and triphosphate (3'-ethyntlcytidine 5'-diphosphate, 3'-ethyntlcytidine 5'-triphosphate). 3'-Ethyntlcytidine 5'-triphosphate is an active metabolite that can inhibit RNA polymerase I competitively. IVS5 + 5 G > A mutation would affect the expression level of the UCK2 transcript and result in decreased sensitivity to ECyd. The UCK2 is a key drug-response predictive marker for innate or acquired resistance to uridine/cytidine-type nucleoside analogs
drug target
inhibition of enzyme (UCK2) induces nucleolar stress, probably by depleting nucleotide biosynthesis, thereby destabilising ribosomal biogenesis and subsequently causing cancer cell arrest and apoptotic cell death induction
malfunction
mutation H117Y of UCK2 results in a loss of uridine phosphorylation activity of the enzyme
malfunction
overexpression of uridine-cytidine kinase 2 correlates with breast cancer progression and poor prognosis. UCK2, along with other genes involved in the 5-FU anabolic pathway, produces a phenotype of cell sensitivity to 5-FU folxadlowing knockdown
malfunction
probable ribosomal stress condition during inhibition of the UCK2 enzyme, overview. The released and subsequent activation of p53 leads towards apoptosis induction
malfunction
role of a uridine/cytidine kinase 2 mutation in cellular sensitiveness toward 3'-ethynylcytidine (ECyd) treatment of human cancer cells. The splice-site mutation of the UCK2 gene resulting in the IVS5+5 G>A variant affects the expression level of the UCK2 transcript, causing decreased sensitivity to ECyd. The IVS5+5 G>A variant generates an aberrant mRNA transcript, namely, truncated mRNA is produced and normal mRNA levels are markedly decreased in the ECyd-resistant cancer cell line HT1080. Relationship of UCK2 mutations and drug sensitivity with ECyd in several cancer cell lines, overview. Detection of the aberrant mRNA transcript in the ECyd/EUrd-resistant cancer cells with the IVS5 +5 A/A genotype
metabolism
UCK2 is feedback inhibited by UTP and CTP to adjust cellular needs and prevent overproduction of the nucleotides. In the course of cancer cell proliferation, these nucleotides are continuously synthesized to sustain protein synthesis. During gene degradation, some NMPs are released and recycled via the salvage pathway by the action of UCK2, thereby facilitating the prevention of energy loss and the waste of valuable precursors. Molecular crosstalks between UCK2 and cell death, the role of ribosomal proteins, MDM2 and p53 in regulation of cell death, and the role of UCK2 in regulation of cell death
metabolism
the enzyme is responsible for the phosphorylation of uridine and cytidine to their corresponding monophosphate in a salvage pathway of pyrimidine nucleotides biosynthesis
physiological function
a nucleosidic medicine, 1-(3-C-ethynyl-beta-D-ribopentofuranosyl) cytosine [3'-ethynylcytidine (ECyd)], is a potent inhibitor of RNA polymerase I and shows anticancer activity to various human solid tumors in vitro and in vivo. ECyd is phosphorylated to 3'-ethynylcytidine 5'-monophosphate by uridine/cytidine kinase 2 (UCK2) and subsequently further to diphosphate and triphosphate (3'-ethynylcytidine 5'-diphosphate, 3'-ethynylcytidine 5'-triphosphate). 3'-ethynylcytidine 5'-triphosphate is an active metabolite that can inhibit RNA polymerase I competitively, causing cancer cell death
physiological function
enzyme activity in two panels of tumor cell lines and xenograft cells correlated only with UCK2-mRNA expression, but not with UCK1-mRNA. Moreover, accumulation of RX-3117 nucleotides correlates with UCK2 expression
physiological function
the pyrimidine salvage enzyme uridine-cytidine kinase 2 (UCK2) is necessary for uridine salvage. Biological significance of UCK2 in the uridine salvage is measured by incorporating exogenous 5-ethynyl-uridine (5-EU) specifically into cellular RNA
physiological function
UCK2 is responsible for the phosphorylation of uridine and cytidine to their corresponding monophosphate in a salvage pathway of pyrimidine nucleotides biosynthesis. Uridine-cytidine kinase 2 (UCK2) is linked to cell apoptosis induction. Molecular crosstalk involving UCK2 protein and cancer cell death through cell cycle arrest and triggering of apoptosis involving proteins, MDM2 and the subsequent activation of p53. UCK2 is also involved in the phosphorylation of ribonucleoside analogues, 5-azacytidine, cyclopentenyl cytosine/uracil, 5-fluorocytidine, 6-azauridine, 3-deazauridine, 5-fluorouridine as well as ethynyl cytidine and uridine. These cytotoxic drugs depends on the action of the UCK2 enzyme to sequentially transformed into nucleoside 5'-triphosphate, thereby interfering with gene synthesis vital for metabolic processes required for cancer cell growth and maintenance
physiological function
uridine-cytidine kinase (UCK) 2 is a rate-limiting enzyme involved in the salvage pathway of pyrimidine-nucleotide biosynxadthesis. Isozyme UCK2 is overexpressed in many types of cancer and may play a crucial role in activating antitumor prodrugs in human cancer cells. The isozyme catalyzes the phosphorylation of urixaddine and cytidine to form uridine monophosphate (UMP) and cytidine monophosphate (CMP) with efficiency 15 to 20fold higher than that of ubiquitously expressed isozyme UCK1
physiological function
uridine-cytidine kinase (UCK) is one of the enzymes in the nucleoside salvage pathway. UCK generally converts both cytidine and uridine to nucleoside monophosphate using ATP as the phosphate donor
additional information
uridine phosphorylation activity commonly depends on a single residue in the UCK family. Structure comparison of Thermus thermophilus enzyme ttCK and human enzyme hsUCK2
additional information
-
uridine phosphorylation activity commonly depends on a single residue in the UCK family. Structure comparison of Thermus thermophilus enzyme ttCK and human enzyme hsUCK2
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Drake, J.C.; Stoller, R.G.; Chabner, B.A.
Characteristics of the enzyme uridine-cytidine kinase isolated from a cultured human cell line
Biochem. Pharmacol.
26
64-66
1977
Homo sapiens
brenda
Shen, F.; Look, K.Y.; Yeh, Y.A.; Weber, G.
Increased uridine kinase (ATP: uridine 5'-phosphotransferase; EC 2.7.1.48) activity in human and rat tumors
Cancer Biochem. Biophys.
16
1-15
1998
Homo sapiens, Rattus norvegicus
brenda
Koizumi, K.; Shimamoto, Y.; Azuma, A.; Wataya, Y.; Matsuda, A.; Sasaki, T.; Fukushima, M.
Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells
Int. J. Mol. Med.
8
273-278
2001
Escherichia coli, Homo sapiens, Mus musculus, Saccharomyces cerevisiae
brenda
Van Rompay, A.R.; Norda, A.; Linden, K.; Johansson, M.; Karlsson, A.
Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases
Mol. Pharmacol.
59
1181-1186
2001
Homo sapiens (Q9BZX2), Homo sapiens (Q9HA47)
brenda
Suzuki, N.N.; Koizumi, K.; Fukushima, M.; Matsuda, A.; Inagaki, F.
Crystallization and preliminary X-ray analysis of human uridine-cytidine kinase 2
Acta Crystallogr. Sect. D
59
1477-1478
2003
Homo sapiens (Q9BZX2), Homo sapiens
brenda
Appleby, T.C.; Larson, G.; Cheney, I.W.; Walker, H.; Wu, J.Z.; Zhong, W.; Hong, Z.; Yao, N.
Structure of human uridine-cytidine kinase 2 determined by SIRAS using a rotating-anode X-ray generator and a single samarium derivative
Acta Crystallogr. Sect. D
61
278-284
2005
Homo sapiens (Q9BZX2), Homo sapiens
brenda
Murata, D.; Endo, Y.; Obata, T.; Sakamoto, K.; Syouji, Y.; Kadohira, M.; Matsuda, A.; Sasaki, T.
A crucial role of uridine/cytidine kinase 2 in antitumor activity of 3'-ethynyl nucleosides
Drug Metab. Dispos.
32
1178-1182
2004
Homo sapiens
brenda
Suzuki, N.N.; Koizumi, K.; Fukushima, M.; Matsuda, A.; Inagaki, F.
Structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase
Structure
12
751-764
2004
Homo sapiens (Q9BZX2), Homo sapiens
brenda
Glavas-Obrovac, L.; Karner, I.; Stefanic, M.; Kasnar-Samprec, J.; Zinic, B.
Metabolic effects of novel N-1-sulfonylpyrimidine derivatives on human colon carcinoma cells
Farmaco
60
479-483
2005
Homo sapiens
brenda
Niemeyer, T.; Dietz, C.; Fairbanks, L.; Schroeder-Printzen, I.; Henkel, R.; Loeeffler, M.
Evaluation of uridine metabolism in human and animal spermatozoa
Nucleosides Nucleotides Nucleic Acids
25
1215-1219
2006
Homo sapiens
brenda
Jukic, L.V.; Duvnjak, M.; Wu, C.H.; Wu, G.Y.
Human uridine-cytidine kinase phosphorylation of ribavirin: a convenient method for activation of ribavirin for conjugation to proteins
J. Biomed. Sci.
15
205-213
2008
Homo sapiens
brenda
Smith, A.J.; Li, Y.; Houk, K.N.
Quantum mechanics/molecular mechanics investigation of the mechanism of phosphate transfer in human uridine-cytidine kinase 2
Org. Biomol. Chem.
7
2716-2724
2009
Homo sapiens (Q9BZX2), Homo sapiens
brenda
van Kuilenburg, A.B.; Meinsma, R.
The pivotal role of uridine-cytidine kinases in pyrimidine metabolism and activation of cytotoxic nucleoside analogues in neuroblastoma
Biochim. Biophys. Acta
1862
1504-1512
2016
Homo sapiens (Q9BZX2), Homo sapiens (Q9HA47)
brenda
Malami, I.; Abdul, A.B.; Abdullah, R.; Bt Kassim, N.K.; Waziri, P.; Christopher Etti, I.
In silico discovery of potential uridine-cytidine kinase 2 inhibitors from the rhizome of Alpinia mutica
Molecules
21
417
2016
Homo sapiens (Q9BZX2)
brenda
Sato, A.; Takano, T.; Hiramoto, A.; Naito, T.; Matsuda, A.; Fukushima, M.; Wataya, Y.; Kim, H.S.
Role of the uridine/cytidine kinase 2 mutation in cellular sensitiveness toward 3-ethynylcytidine treatment of human cancer cells
Anticancer Drugs
28
781-786
2017
Homo sapiens (Q9BZX2), Homo sapiens
brenda
Tomoike, F.; Nakagawa, N.; Fukui, K.; Yano, T.; Kuramitsu, S.; Masui, R.
Indispensable residue for uridine binding in the uridine-cytidine kinase family
Biochem. Biophys. Rep.
11
93-98
2017
Thermus thermophilus (Q5SKR5), Homo sapiens (Q9BZX2), Homo sapiens, Thermus thermophilus DSM 579 (Q5SKR5), Thermus thermophilus ATCC 27634 (Q5SKR5)
brenda
Malami, I.; Abdul, A.B.
Involvement of the uridine cytidine kinase 2 enzyme in cancer cell death a molecular crosstalk between the enzyme and cellular apoptosis induction
Biomed. Pharmacother.
109
1506-1510
2019
Homo sapiens (Q9BZX2)
brenda
Okesli-Armlovich, A.; Gupta, A.; Jimenez, M.; Auld, D.; Liu, Q.; Bassik, M.C.; Khosla, C.
Discovery of small molecule inhibitors of human uridine-cytidine kinase 2 by high-throughput screening
Bioorg. Med. Chem. Lett.
29
2559-2564
2019
Homo sapiens (Q9BZX2), Homo sapiens
brenda
Mohamed, M.; Dirar, A.; Hamdoun, S.
Discovery of two diacetylene glycosides as human uridine-cytidine kinase 2 inhibitors An in silico approach
J. Appl. Pharm. Sci.
6
034-039
2016
Homo sapiens (Q9BZX2)
-
brenda
Shen, G.; He, P.; Mao, Y.; Li, P.; Luh, F.; Ding, G.; Liu, X.; Yen, Y.
Overexpression of uridine-cytidine kinase 2 correlates with breast cancer progression and poor prognosis
J. Breast Cancer
20
132-141
2017
Homo sapiens (Q9BZX2), Homo sapiens
brenda
Meinsma, R.; van Kuilenburg, A.B.
Purification, activity, and expression levels of two uridine-cytidine kinase isoforms in neuroblastoma cell lines
Nucleosides Nucleotides Nucleic Acids
35
613-618
2016
Homo sapiens (Q9BZX2), Homo sapiens (Q9HA47), Homo sapiens
brenda
Sarkisjan, D.; Julsing, J.R.; Smid, K.; de Klerk, D.; van Kuilenburg, A.B.; Meinsma, R.; Lee, Y.B.; Kim, D.J.; Peters, G.J.
The cytidine analog fluorocyclopentenylcytosine (RX-3117) is activated by uridine-cytidine kinase 2
PLoS ONE
11
e0162901
2016
Homo sapiens (Q9BZX2), Homo sapiens
brenda
Yu, S.; Li, X.; Guo, X.; Zhang, H.; Qin, R.; Wang, M.
UCK2 upregulation might serve as an indicator of unfavorable prognosis of hepatocellular carcinoma
IUBMB Life
71
105-112
2019
Homo sapiens (Q9BZX2), Homo sapiens (Q9HA47), Homo sapiens (Q9NWZ5), Homo sapiens
brenda